Roche melanoma drug extends life more than a yr-study - msnbc.com

The results from an abstract, or brief summary, of the study showed that Zelboraf led to a median overall survival of 13.2 months compared with 9.6 months for those who received dacarbazine chemotherapy. That translates into a 38 percent ...

Vical's CEO Presents at Bank of America Merrill Lynch Health Care Conference Call (Transcript) - Seekingalpha.com

The study is randomized 2:2:1 twice the number of patients get Allovectin-7, so there will be about 260 patients getting Allovectin-7 and about 130 getting Dacarbazine. The study is not blinded to the doctors and the patients. It’s blinded to us ...

Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - new market research report - Transworld News

Cytotoxics such as dacarbazine and other off-label drugs including temozolomide, cisplatin and paclitaxel. The growth of the market is primarily due to the new product approvals and increase in the incidence rates during the forecast period. Due to these ...

Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. - 7thspace.com

In August 2010 she was enrolled into the BRIM3 trial and after the randomization process she received dacarbazine. After two cycles, there was evidence of disease progression in her peritoneum and lung. For this reason, she was enrolled into another ...

Roche Holding Ltd. : Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012 - 4-traders (press release)

BRIM3: Updated overall survival (OS) results for BRIM3, a Phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E mutated melanoma. Abstract #8502.

Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2012 - TMCnet

Only three patients experienced grade 4 adverse events. Array anticipates top-line results for the Phase 2 trial with selumetinib in combination with dacarbazine versus dacarbazine alone as first-line treatment in patients with BRAF-mutant ...

Dabrafenib Safe in Melanoma With Brain Mets - MedPage Today

There currently are two trials in the works with dabrafenib in melanoma: a phase II study in patients with asymptomatic brain metastases and a phase III randomized, controlled trial of dabrafenib compared with dacarbazine (Dtic-Dome).

BUYINS.NET: BRKR, MSHL, DCTH, REDF, CDZI, GIGA Are Seasonally Ripe To Go Down In the Next Five Weeks - TMCnet

dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II ...

For the Treatment of Advanced Melanoma, Oncologists Report that Yervoy and Zelboraf have Joined Temodar as the Leading Agents for First-line Therapy - PharmiWeb

In terms of level of interest with late stage products in development for advanced melanoma, medical oncologists were most interested in Yervoy in combination with another agent such as Zelboraf, Merck & Co.’s Temodar or generic dacarbazine. Medical ...